Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03311308 · ClinicalTrials.gov registry record · Phase 1
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
A Phase 1 study of Advanced Melanoma, sponsored by Yana Najjar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03311308: Recruiting Phase 1 study of Advanced Melanoma, sponsored by Yana Najjar.
NCT03311308 is a Phase 1 study of Advanced Melanoma that is actively recruiting participants, run by Yana Najjar. The registered enrollment target is 30 participants, below the 170-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03311308, a Phase 1 study of Advanced Melanoma, is actively recruiting participants, sponsored by Yana Najjar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
Primary Outcome
determine the cell cycle status
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Pembrolizumab Injection [Keytruda]
Study Locations (1)
Pennsylvania
- Univ of Pittsburgh Medical Center Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
What NCT03311308 shows while recruiting
NCT03311308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 170-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT03311308 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03311308 about?
NCT03311308 is a clinical study titled "A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma". The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
What is the current status of trial NCT03311308?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-02-07. Estimated completion is 2029-12.
What conditions does trial NCT03311308 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT03311308?
The interventions under investigation include: Metformin (DRUG), Pembrolizumab Injection [Keytruda] (DRUG).
Who is sponsoring clinical trial NCT03311308?
This trial is sponsored by Yana Najjar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03311308 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03311308's enrollment target sits among peer trials
30 17th of 21 higher than 5 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Naltrexone and Propranolol Combined With Immunotherapy
RECRUITING · Phase 1
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
RECRUITING · Phase 1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI